Drugs / INV-9956
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06609005 | Jan 2025 → Jan 2028 expected | castration-resistant prostate carcinoma | Shenzhen Ionova Life Sciences Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INV-9956 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06609005 ↗ |